US 11,897,887 B2
sGC stimulators
Glen Robert Rennie, Somerville, MA (US); Paul Allan Renhowe, Sudbury, MA (US); Takashi Nakai, Newton, MA (US); Ara Mermerian, Waltham, MA (US); and Helen Cumberbatch, Cambridge, MA (US)
Assigned to Tisento Therapeutics Inc., Cambridge, MA (US)
Appl. No. 16/955,494
Filed by Tisento Therapeutics Inc., Cambridge, MA (US)
PCT Filed Dec. 19, 2018, PCT No. PCT/US2018/066547
§ 371(c)(1), (2) Date Dec. 16, 2020,
PCT Pub. No. WO2019/126354, PCT Pub. Date Jun. 27, 2019.
Claims priority of provisional application 62/607,619, filed on Dec. 19, 2017.
Prior Publication US 2020/0377508 A1, Dec. 3, 2020
Int. Cl. C07D 487/04 (2006.01); C07F 9/09 (2006.01); A61K 45/06 (2006.01)
CPC C07D 487/04 (2013.01) [C07F 9/09 (2013.01); A61K 45/06 (2013.01)] 24 Claims
 
1. A compound of Formula I, or a pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
wherein:
Y is independently N or C;
ring B is a phenyl or a 5 or 6-membered heteroaryl ring, containing 1 or 2 ring heteroatoms independently selected from N, O and S;
n is an integer selected from 0 to 3; and each JB is independently halogen, —CN, a C1-6 aliphatic or —ORB;
wherein each JB that is a C1-6 aliphatic is optionally and independently substituted with up to 3 instances of R3;
each RB is independently hydrogen or a C1-6 aliphatic; said C1-6 aliphatic represented by RB is optionally and independently substituted with up to 3 instances of R3a;
each R3 and R3a is, in each instance, independently halogen, —CN, C1-4 alkyl, C1-4 haloalkyl, —O(C1-4 alkyl) or —O(C1-4 haloalkyl);
Z is selected from the group consisting of hydrogen, —P(O)(OH)2, —P(O)(OH)O−M+, —P(O)(O−)2 (M+)2, —P(O)(O−)2 D2+and —P(O)(O-Benzyl)2; wherein M+ is a pharmaceutically acceptable monovalent cation and D2+is a pharmaceutically acceptable divalent cation;
m is 0 or 1;
R1 is C1-4 alkyl, C1-4 fluoroalkyl, —C(O)NH2 or hydrogen; and
R2 is C1-4 alkyl, C1-4 fluoroalkyl or hydrogen;
both instances of R4 are simultaneously hydrogen or both instances of R4, together with the carbon atom to which they are attached form a carbonyl group;
JD is hydrogen, halogen, methoxy or —CN
p is 1 or 2; and
each JC is independently hydrogen, halogen, C1-4 aliphatic, C1-4 alkoxy or —CN; wherein each said C1-4 aliphatic and each said C1-4 alkoxy is optionally and independently substituted by up to 3 instances of C1-4 alkoxy, C1-4 haloalkoxy, —OH or halogen.